Switch theme
Sign up to access all valuation multiples
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
1925
49.3K+
LTM Revenue $31.4B
LTM EBITDA $8.2B
$74.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Takeda Pharmaceuticals has a last 12-month revenue (LTM) of $31.4B and a last 12-month EBITDA of $8.2B.
In the most recent fiscal year, Takeda Pharmaceuticals achieved revenue of $29.3B and an EBITDA of $6.2B.
Takeda Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Takeda Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $31.4B | XXX | $29.3B | XXX | XXX | XXX |
| Gross Profit | $20.8B | XXX | $19.5B | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $8.2B | XXX | $6.2B | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $2.5B | XXX | $2.2B | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $897M | XXX | $989M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $30.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Takeda Pharmaceuticals's stock price is JPY 4314 (or $30).
Takeda Pharmaceuticals has current market cap of JPY 6.74T (or $46.2B), and EV of JPY 10.85T (or $74.4B).
See Takeda Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $74.4B | $46.2B | XXX | XXX | XXX | XXX | $0.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Takeda Pharmaceuticals has market cap of $46.2B and EV of $74.4B.
Takeda Pharmaceuticals's trades at 2.6x EV/Revenue multiple, and 11.2x EV/EBITDA.
Equity research analysts estimate Takeda Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Takeda Pharmaceuticals has a P/E ratio of 51.6x.
See valuation multiples for Takeda Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46.2B | XXX | $46.2B | XXX | XXX | XXX |
| EV (current) | $74.4B | XXX | $74.4B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.1x | XXX | 11.2x | XXX | XXX | XXX |
| EV/EBIT | 29.7x | XXX | 28.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 51.6x | XXX | 36.0x | XXX | XXX | XXX |
| EV/FCF | 13.8x | XXX | 41.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTakeda Pharmaceuticals's last 12 month revenue growth is 0%
Takeda Pharmaceuticals's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
Takeda Pharmaceuticals's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Takeda Pharmaceuticals's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Takeda Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Takeda Pharmaceuticals acquired XXX companies to date.
Last acquisition by Takeda Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Takeda Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Takeda Pharmaceuticals founded? | Takeda Pharmaceuticals was founded in 1925. |
| Where is Takeda Pharmaceuticals headquartered? | Takeda Pharmaceuticals is headquartered in Japan. |
| How many employees does Takeda Pharmaceuticals have? | As of today, Takeda Pharmaceuticals has 49.3K+ employees. |
| Who is the CEO of Takeda Pharmaceuticals? | Takeda Pharmaceuticals's CEO is Mr. Christophe Weber. |
| Is Takeda Pharmaceuticals publicy listed? | Yes, Takeda Pharmaceuticals is a public company listed on TKS. |
| What is the stock symbol of Takeda Pharmaceuticals? | Takeda Pharmaceuticals trades under 4502 ticker. |
| When did Takeda Pharmaceuticals go public? | Takeda Pharmaceuticals went public in 1949. |
| Who are competitors of Takeda Pharmaceuticals? | Similar companies to Takeda Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Takeda Pharmaceuticals? | Takeda Pharmaceuticals's current market cap is $46.2B |
| What is the current revenue of Takeda Pharmaceuticals? | Takeda Pharmaceuticals's last 12 months revenue is $31.4B. |
| What is the current revenue growth of Takeda Pharmaceuticals? | Takeda Pharmaceuticals revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Takeda Pharmaceuticals? | Current revenue multiple of Takeda Pharmaceuticals is 2.4x. |
| Is Takeda Pharmaceuticals profitable? | Yes, Takeda Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Takeda Pharmaceuticals? | Takeda Pharmaceuticals's last 12 months EBITDA is $8.2B. |
| What is Takeda Pharmaceuticals's EBITDA margin? | Takeda Pharmaceuticals's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Takeda Pharmaceuticals? | Current EBITDA multiple of Takeda Pharmaceuticals is 9.1x. |
| What is the current FCF of Takeda Pharmaceuticals? | Takeda Pharmaceuticals's last 12 months FCF is $5.4B. |
| What is Takeda Pharmaceuticals's FCF margin? | Takeda Pharmaceuticals's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Takeda Pharmaceuticals? | Current FCF multiple of Takeda Pharmaceuticals is 13.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
